Journal Mobile Options
Table of Contents
Vol. 14, No. 3, 2002
Issue release date: September 2002
Dement Geriatr Cogn Disord 2002;14:161–166
(DOI:10.1159/000063606)

Cerebral Amyloid Angiopathy, White Matter Lesions and Alzheimer Encephalopathy – A Histopathological Assessment

Haglund M. · Englund E.
Division of Neuropathology, Department of Pathology and Cytology, University of Lund, Lund, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

To test the hypothesis that the cerebral amyloid angiopathy (CAA) of Alzheimer’s disease (AD) is quantitatively associated with white matter lesions (WML), the brains of 63 demented patients exhibiting varying degrees of Alzheimer encephalopathy (AE) were examined, along with those of 10 nondemented control cases. The ratio of amyloid-positive to amyloid-negative vessels in the leptomeninges of the frontal pole from each patient was calculated subsequent to microscopical examination, and the severity of WML was graded according to previously published criteria. In AD cases without a significant component of vascular dementia, the level of CAA was found to correlate with the degree of WML diagnosed and graded by neuropathology. Neither age nor severity of AE correlated significantly with WML. There may be several reasons for the conflicting results of this study vis-à-vis earlier investigations; the roles played by different methods of staining, CAA quantitation and patient subgroup selection are also discussed.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Briley DP, Haroon S, Sergent SM, Thomas S: Does leukoaraiosis predict morbidity and mortality? Neurology 2000;54:90–94.
  2. Hirono N, Kitagaki H, Kazui H, Hashimoto M, Mori E: Impact of white matter changes on clinical manifestation of Alzheimer’s disease. A quantitative study. Stroke 2000;31:2182–2188.

    External Resources

  3. Starkstein SE, Sabe L, Vázquez S, Di Lorenzo G, Martínez A, Petracca G, Tesón A, Chemerinski E, Leiguarda R: Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1997;63:66–73.
  4. Leys D, Englund E, Del Ser T, Inzitari D, Fazekas F, Bornstein N, Erkinjuntti T, Bowler JV, Pantoni L, Parnetti L, De Reuck J, Ferro J, Bogousslavsky J: White matter changes in stroke patients. Relationship with stroke subtype and outcome. Eur Neurol 1999;42:67–75.
  5. Tarvonen-Schroeder S, Roytta M, Raiha I, Kurki T, Rajala T, Sourander L: Clinical features of leukoaraiosis. J Neurol Neurosurg Psychiatry 1996;60:431–436.
  6. Englund E: Neuropathology of white matter disease: Parenchymal changes; in Pantoni L, Inzitari D, Wallin A (eds): The Matter of White Matter. Clinical and Pathophysiological Aspects of White Matter Disease Related to Cognitive Decline and Vascular Dementia. Curr Issues Neurodegen Dis. Utrecht, Academic Pharmaceutical Productions, 2000, vol 10, pp 223–246.
  7. Pantoni L, Garcia JH: Pathogenesis of leukoaraiosis. A review. Stroke 1997;28:652–659.
  8. Gray F, Dubas F, Roullet E, Escourolle R: Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985;18:54–59.
  9. Erkinjuntti T, Benavente O, Eliasziw M, Munoz DG, Sulkava R, Haltia M, Hachinski V: Diffuse vacuolization (spongiosis) and arteriolosclerosis in the frontal white matter occurs in vascular dementia. Arch Neurol 1996;53:325–332.
  10. Janota I, Mirsen TR, Hachinski VC, Lee DH, Merskey H: Neuropathologic correlates of leuko-araiosis. Arch Neurol 1989;46:1124–1128.
  11. Munoz DG, Hastak SM, Harper B, Lee D, Hachinski VC: Pathologic correlates of increased signals of the centrum ovale on magnetic resonance imaging. Arch Neurol 1993;50:492–497.
  12. Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W: Histopathologic correlates of white matter changes on MRI in Alzheimer’s disease and normal aging. Neurology 1995;45:883–888.
  13. Tomimoto H, Akiguchi I, Akiyama H, Ikeda K, Wakita H, Lin JX, Budka H: Vascular changes in white matter lesions of Alzheimer’s disease. Acta Neuropathol 1999;97:629–634.
  14. Cadavid D, Mena H, Koeller K, Frommelt RA: Cerebral β-amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol 2000;59:768–773.
  15. Olichney JM, Hansen LA, Hofstetter R, Grundman R, Katzman R, Thal LJ: Cerebral infarction in Alzheimer’s disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 1995;52:702–708.
  16. Brun A, Englund E: Regional pattern of degeneration in Alzheimer’s disease: Neuronal loss and histopathological grading. Histopathology 1981;5:549–564.
  17. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). 2. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–486.
  18. Braak E, Braak H, Mandelkow EM: A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol (Berl) 1994;87:554–567.
  19. Brun A, Gustafson L: The longitudinal dementia study: A 25-year perspective on neuropathology, differential diagnosis and treatment; in Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P (eds): Alzheimer’s Disease – Advances in Clinical and Basic Research. New York, John Wiley, 1993, pp 3–18.
  20. Englund E, Brun A: White matter changes in dementia of Alzheimer’s type: the difference in vulnerability between cell compartments. Histopathology 1990;16:433–439.
  21. Ferrer I, Bella R, Serrano MT, Martí E, Guionnet N: Arteriosclerotic leucoencephalopathy in the elderly and its relation to white matter lesions in Binswanger’s disease, multi-infarct encephalopathy and Alzheimer’s disease. J Neurol Sci 1990;98:37–50.
  22. Imaoka K, Kobayashi S, Fujihara S, Shimode K, Nagasaki M: Leukoencephalopathy with cerebral amyloid angiopathy: A semiquantitative and morphometric study. J Neurol 1999;246:661–666.
  23. Brilliant M, Hughes L, Anderson D, Ghobrial M, Elble R: Rarefied white matter in patients with Alzheimer Disease. Alzheimer Dis Assoc Disord 1995;9:39–46.
  24. Greenberg SM, Vonsattel JPG: Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997;28:1418–1422.
  25. Englund E: Neuropathology of white matter changes in Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 1998;9(suppl 1):6–12.
  26. Bronge L, Bogdanovic N, Wahlund LO: Postmortem MRI and histopathology of white matter changes in Alzheimer brains. A quantitative, comparative study. Dement Geriatr Cogn Disord 2002;13(4):205–212.
  27. Linke RP: Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Arch 2000;436:439–448.
  28. Verbeek MM, Van Nostrand WE, Otte-Holler I, Wesseling P, De Waal RM: Amyloid-β-induced degeneration of human brain pericytes is dependent on the apolipoprotein E genotype. Ann NY Acad Sci 2000;903:187–199.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50